Ibaraki, Japan

Kyoichi Maeno


Average Co-Inventor Count = 8.1

ph-index = 3

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 1997-2003

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Kyoichi Maeno: Innovator in Pharmaceutical Chemistry

Introduction

Kyoichi Maeno is a distinguished inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target central nervous system disorders. With a total of 4 patents to his name, Maeno's work has the potential to impact the treatment of various mental health conditions.

Latest Patents

Among his latest patents, Maeno has developed thiazolobenzoimidazole derivatives and a tricyclic pyrrole or pyrazole derivative. The latter is represented by a specific general formula and is noted for its strong affinity and selectivity for the 5-HT receptor. This compound shows promise in treating central nervous system diseases, including sexual disorders, eating disorders, anxiety, depression, and sleeping disorders.

Career Highlights

Kyoichi Maeno has built a reputable career at Yamanouchi Pharmaceutical Company Ltd., where he has been instrumental in advancing pharmaceutical research. His innovative approach to drug development has garnered attention in the scientific community, and his patents reflect his commitment to improving patient outcomes.

Collaborations

Maeno has collaborated with notable colleagues such as Shuichi Sakamoto and Itsuro Shimada. These partnerships have fostered a collaborative environment that enhances the research and development process within the pharmaceutical industry.

Conclusion

Kyoichi Maeno's contributions to pharmaceutical chemistry exemplify the impact of innovation in addressing complex health issues. His work continues to pave the way for new treatments that can significantly improve the quality of life for many individuals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…